Table 3:
Differentiation of various groups with T1, T2 and ADC and their combinations.
| Groups Compared |
T1 AUC | T2 AUC | ADC AUC |
T1+T2 AUC |
T1+ ADC AUC |
T2+ ADC AUC |
T1+ T2+ ADC AUC |
Highest AUC# |
|---|---|---|---|---|---|---|---|---|
| All Prostate cancers versus Non-Cancers | ||||||||
| Prostate Cancer (n=63) vs. Prostatitis (n=15) | 0.60 (0.41-0.78) | 0.71* (0.55-0.88) | 0.79* (0.65-0.93) | 0.71 (0.54-0.88) | 0.76 (0.59-0.92) | 0.79 (0.64-0.94) | 0.79 (0.65-0.95) | ADC (0.79) comparable to T2 (0.71) Difference between two AUCs not significant (p=0.37) |
| Prostate Cancer (n=63) vs. Negative Biopsies (n=26) | 0.67* (0.55-0.79) | 0.62 (0.49-0.75) | 0.80* (0.69-0.90) | 0.67 (0.55-0.79) | 0.83* (0.74-0.93) | 0.80 (0.70-0.93) | 0.83 (0.74-0.93) | T1+ADC (0.83) |
| Prostate Cancer (n=63) vs. Non-cancers (n=41) | 0.64* (0.53-0.75) | 0.66* (0.55-0.77) | 0.80* (0.71-0.89) | 0.68 (0.57-0.78) | 0.80* (0.71-0.89) | 0.80 (0.71-0.89) | 0.80 (0.71-0.89) | T1+ADC (0.80) ADC (0.80) |
| Clinically-significant (CS) cancers versus other histologic groups | ||||||||
| CS Cancer (n=53) vs. Low-grade cancers (n=10) | 0.48 (0.25-0.71) [0.553] | 0.77* (0.61-0.92) [0.012] | 0.84* (0.71-0.97) [0.002] | 0.76 (0.61-0.92) | 0.85 (0.74-0.96) | 0.91* (0.82-0.99) | 0.90 (0.79-1.00) | T2+ADC (0.91) |
| CS Cancer (n=53) vs. Non-cancers (n=41) | 0.64* (0.53-0.76) [0.028] | 0.70* (0.59-0.81) [0.029] | 0.84* (0.76-0.92) [<0.0001] | 0.70 (0.60-0.81) | 0.85 (0.77-0.93) | 0.86* (0.78-0.93) | 0.86 (0.74-0.94) | T2+ADC (0.86) |
| CS Cancer (n=53) vs. Non-cancers + Low-grade cancers (n=51) | 0.61 (0.50-0.72) [0.064] | 0.71* (0.61-0.81) [0.0002] | 0.84* (0.76-0.92) [<0.0001] | 0.70 (0.60-0.80) | 0.85 (0.77-0.92) | 0.86* (0.79-0.93) | 0.86 (0.80-0.93) | T2+ADC (0.86) |
*
Indicate models with significant variables (p < 0.05) obtained from generalized estimating equation (GEE) logistic regression analysis. The numbers in parenthesis indicate 95% confidence intervals and numbers in brackets indicate P-value for the variables in the univariate models.
#
The highest AUC represents model(s) with significant variables after GEE logistic regression analysis.
Clinically-significant cancers included all cancers with Gleason score ≥ 7 while low-grade cancers was denoted by cancers with Gleason score =6
Negative biopsy =Targeted lesions with biopsy report of benign prostatic tissue